RATIO THERAPEUTICS HAS SUCCESSFULLY DOSED THE FIRST COHORT IN ITS PHASE 1/2 STUDY EVALUATING A NOVEL FAP-TARGETED RADIOPHARMACEUTICAL IN PATIENTS WITH LATE-STAGE AGGRESSIVE SARCOMAS
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.